对抗凝血剂的知识,INR控制和与华法林相关的不良事件之间的关联:一个横截面研究
Noor Kokash1, Lobna Gharaibeh2, Sura Al Zoubi3
1Biopharmaceutics and Clinical Pharmacy Department, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, 19328, Jordan.
BMC research notes
|March 5, 2025
概括
大多数华法林患者缺乏足够的治疗知识,影响了INR控制,增加了血栓和出血的风险. 高等教育与更好的理解相关,而长时间使用可能会降低警.
科学领域:
- 药理学 药理学是指药理学的学科.
- 患者教育 患者教育
- 内部医学 内部医学
背景情况:
- 华法林是一种关键的抗凝药药物,需要患者坚持并了解有效性.
- 患者对华法林治疗的知识不足,可能导致治疗结果不佳,包括血栓塞栓事件和出血并发症.
研究的目的:
- 在200名门诊患者中评估对华法林治疗的知识和理解.
- 为了确定与充足的华法林知识相关的因素.
主要方法:
- 横截面观测研究.
- 与200名使用华法林的门诊患者进行面对面的采访.
- 使用OAK问卷来评估华法林知识.
主要成果:
- 近70%的患者对他们的华法林治疗知识不足.
- 只有三分之一的患者保持其INR在目标范围内.
- 更高的教育水平与更好的华法林知识相关,而更长时间的华法林使用与知识的减少有关.
- 充分的知识与保持INR在目标范围内有关.
结论:
- 华法林患者中很大一部分人缺乏足够的知识,这凸显了改善患者教育的迫切需要.
- 干预措施应侧重于提高患者的理解力,特别是长期使用者和教育程度较低的人.
- 足够的患者知识与更好的抗凝血控制有关 (目标范围内的INR).
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
590
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
590
Therapeutic Index
4.0K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
454
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
454
Pharmacovigilance
764
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
764
Disorders of Hemostasis
676
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
676


